The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Imm have released the news with Avion when the deal was done. The links you have provided for Mammoth are the same kinds of press releases when companies do these kind of deals. One of the points mentioned in the posts is that Avion have not yet acknowledged the deal on their website; this is how most of these releases are done. The links you have provided suffer from the same issues in that it is only on Horizons website and not on Mammoths and for the other deal it is on Mammoths website and not GSKs. So this appears to be the norm it is not a requirement for both companies to put the news on each others websites.
The links to Imm's press releases:
https://www.google.com/amp/s/uk.mobile.reuters.com/article/amp/idUKKBN1Y212Y
Here is a further update:
https://markets.ft.com/data/announce/full?dockey=1323-14412727-0A64HL08QDCR4NA63L3STR8CLM
Avion have in fact publicly acknowledged the deal when the initial announcement was made so there is no need for them to put it on their own website as well:
Art Deas, Chief Executive Officer, Avion Pharmaceuticals added: “Avion is extremely pleased to sign this partnership with ImmuPharma. After in-depth due-diligence around Lupuzor™, its mechanism of action and learnings within the initial Phase III results, we believe that Lupuzor™ has a unique position within lupus that sets it apart from competition, and we are delighted to be extending our footprint within this therapeutic area. With approximately 1.5 million patients in the US suffering from lupus, there is a significant unmet need for a safe and effective drug for this debilitating disease that we believe Lupuzor™ can meet. We look forward to forging a strong and successful relationship with ImmuPharma going forward.”
Yes I agree that news is due and we are waiting for it and this should be due shortly.
News that will have a material impact on the SP.
With a very low number of shares on issue, when this starts moving then the offer moves sharply. Hence the need to drip feed buys. Just try buying in any volume and you will understand what I mean.
Yes just confirms we are waiting for news.
If you have a read you will understand why I am positive from these levels with news about to land anytime soon. I still believe this will be before 18/6
Is there anything in particular I should be looking at?
directors
then
talk
then
interviews
https://www.***************************/immupharma-provides-an-update-on-the-avion-agreement/412804906
where the stars are put in the following: *************interviews - followed by a dot . and then com
Take a read
www.***************************/immupharma-provides-an-update-on-the-avion-agreement/412804906
Coming up as same company for me:
https://www.prnewswire.com/news-releases/avion-pharmaceuticals-llc-named-a-best-place-to-work-in-medical-sales-by-medreps-300981876.html#:~:text=Avion%20Pharmaceuticals%2C%20LLC%2C%20is%20a,the%20quality%20of%20patient%20lives.
According to this link they are classed as one of the major players in the pericarditis area and there is a reference to autoimmune disorders in the link:
"The major players covered in the pericarditis drugs market are Hikma Pharmaceuticals PLC, Takeda Pharmaceuticals Industries Ltd, Avion Pharmaceuticals LLC, Dr. Reddy’s Laboratories Ltd., Mylan N.V., Amneal Pharmaceuticals LLC, Sun Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, and Lupin among others."
https://3wnews.org/uncategorised/1173858/impact-of-covid-19-pericarditis-drugs-market-2020-explores-new-growth-opportunities-hikma-pharmaceuticals-plc-takeda-pharmaceuticals-industries-ltd-avion-pharmaceuticals/
A Google search shows that "chronic or recurring pericarditis is usually the result of autoimmune disorders such as lupus, scleroderma and rheumatoid arthritis. These are disorders in which the body's immune system makes antibodies that mistakenly attack the body's tissues or cells".
Perhaps they have more knowledge of this area than they are being given credit for? The phase 3 trial design will be in partnership with the Imm, Avion and the FDA and they will have the leading practitioners on board so it is not all being led by Avion but they are funding it all.
That's what puzzles me, Avion, a company with no experience at all in bringing drugs to market as a partner. Why not a real drug company? I took a small bet a few weeks ago but await further news before taking more. There is something that doesn't rhyme imo.
Are you thinking of Avon by any chance? Avion are a pharmaceutical company.
News imminent......not long before this starts moving upwards. I think we will be a lot higher come Friday, pre-agm, unless IMM update the market on their meeting with Avion and FDA this week and commercial interest outside of the US.
Stake building the key here.
Zedy,
It's going to be a long long twisty road before we have a readout on any P3 trial ....imo
The real prize will be successful phase 3 trial results for Lupozor in US due to begin later this year. Once trial underway the newsflow will be relentless and this will easily go over 150p prior to announcing results of trial. If successful then double that easily. Patience will be required next 12 months. Rewards huge.
Immupharma the specialist drug discovery and development company announces that the Company’s Annual General Meeting (AGM) confirmed for Thursday, 18 June 2020 @ 10.30am
Correction from my previous post - the AGM is next Thursday, not Wednesday.
Having Avion signed up and on board is massive - with the potential of commercial investment from outside the US by interested parties possible, this really has the potential for transformational change for IMM.
Lets see what news we get, as that's what will ultimately drive the SP.
Patience here, because I think when we do get the news the SP will react and we will likely see this more than double. Last rise saw 22p as the top, but the rise from Nov 19 it was around 32p. I think being patient will see a return in excess of 100% from these levels
Next leg up on the cards - AGM next Wed, so expect us to push upwards towards that date. Should get the details following the meeting with Avion and the FDA and potential commercial partners - I still believe this will be pre-agm
Patience HAlfbutt , Patience :-)
My technical analysis is worth what it's worth but here goes ...
Entry point 13.5p -14p Stop loss. 12.8p
Exit points ..... well that depends on your profile :-)
Everyone to their own points and trades :-)
Ogm4,
Twitter is for .....
Now it doesn't take a rocket scientist to say buy 11-15 range with a stop loss at 6.4p .... lol
IMM target 36.8p vs. current 15-16p range
https://mobile.twitter.com/smallcappick/status/1269574628848123905